SALL4 and neoplasm: The SALL4 positive immunoreactivity was detected in a total of 102 ICC cases (58%), and non-reactivity was validated on tissue sections from 73 cases (42%), whereas non-reactivity was observed on total 28 adjacent non-tumor tissues.